The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur, MBBS, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares findings from a retrospective study comparing outcomes with polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus rituximab and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk diffuse large B-cell lymphoma (DLBCL). Dr Thakur reports that outcomes were superior in the Pola-R-CHP arm. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
